Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEKLON DX
- Development stage
- Unknown
- Lead developer
- Shayana Farm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CEKLON DX is a fixed-dose combination film-coated tablet developed and marketed by Shayana Farm, a pharmaceutical company based in Uzbekistan. It is indicated for the treatment of erectile dysfunction and premature ejaculation in adult men. The medication contains two active ingredients: sildenafil citrate, a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5) that enhances penile blood flow by preventing the degradation of cGMP, and dapoxetine hydrochloride, a short-acting selective serotonin reuptake inhibitor (SSRI) designed to delay ejaculation and improve control over ejaculation. The tablets are typically diamond-shaped, blue, and administered orally approximately one hour before planned sexual activity.
- Brand names
- CEKLON DXCyclone DX
- Other names
- sildenafil citrate + dapoxetine hydrochloridesildenafil + dapoxetine
02
Targets
SERT (Sodium-dependent serotonin transporter)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on CEKLON DX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEKLON DX.